All lobbying filings

ARNOLD & PORTER KAYE SCHOLER LLP

Lobbying for NOVO NORDISK, INC. · Pharmaceutical company.

Filing 1st Quarter - Report

1st Quarter (Jan 1 - Mar 31) 2025 · New Jersey · House · Senate · $80,000.00 income · posted Apr 18, 2025

Official filing document

Bills named in this filing 2

HR 4818
Treat and Reduce Obesity Act of 2023
S 2407
Treat and Reduce Obesity Act of 2023

Lobbying activity 3

Pharmacy

Issues related to pharmacy benefit managers (PBMs) and the 340B Program.

Health Issues

Issues related to pharmacy benefit managers (PBMs) and the 340B program. Issues related to the clinical and overall benefit of anti-obesity medications. Issues related to insulin pricing/affordability.

Medicare/Medicaid

Issues related to CMS coverage of anti-obesity medications, including the Treat and Reduce Obesity Act of 2023 (H.R. 4818 / S. 2407, 118th Congress).

Source: federal Lobbying Disclosure Act filing. Bills are parsed from the activity descriptions.